After About $2.0 Billion In Write-Offs (2010 to 2012), Merck Sells Off Zontivity® US And Canadian Rights — For $25 Million

When Zontivity® was shelved last month, we knew this day would come. It merits scant mention — as it is not remotely material.

Here is the Reuters news brief, of early this morning, just the same — for a complete record:

. . . .Aralez says asset purchase agreement entered into between Merck, and Aralez Pharmaceuticals Trading DAC, unit of Aralez. . .

Asset purchase agreement included an initial upfront payment of $25 million, which was paid from cash on hand. . .

Product rights, packaging, labeling and other responsibilities transferred to Aralez Pharmaceuticals. . .

Onward — quite a come-down.



There are no comments on this post.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: